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Aim. This prospective, multi-center study was designed to evaluate the reproducibility of PV 
isolation guided by the ablation index (AI).  
Methods. A total of 490 consecutive patients with paroxysmal (80.4%) and persistent AF 
underwent first time PV encircling and were divided in four study groups according to 50 
operator’s preference in choosing the ablation catheter (a contact force (ST) or contact force 
surround flow (STSF) catheter) and the AI setting  (330-450 or 380-500 at posterior and 
anterior walls, respectively). Radiofrequency energy was delivered targeting interlesion 
distance ≤ 6 mm. 
Results. At 12 months follow-up a high rate of freedom from AF recurrences was observed 55 
in patients with both paroxysmal and persistent AF (91% vs 83.3%, p=0.039). There was no 
difference in the rate of atrial arrhythmias recurrence among the four study groups (4.5% in 
Group ST330-450, 12.2% in Group ST 380-500, 14.9% in Group STSF330-450, 9.4% in 
Group STSF380-500, p=0.083). Recurrence was also similar between patients treated with a 
ST (8.0%) or STSF catheter (12.1%, p=0.2), within patients targeting an AI settings of 330-60 
450 (10.9%) or 380-500 (10.3%, p=0.64), and among operators (p=0.84 and p=0.75 in 
patients with paroxysmal and persistent AF, respectively). 
Conclusions. An ablation protocol respecting strict criteria for contiguity and quality lesion 
resulted in high rate of one-year freedom from AF recurrence, both in patients with 
paroxysmal and persistent AF, irrespective of the ablation catheters, AI settings, and operator. 65 











In 490 consecutive patients with AF, undergoing first time PV encircling, an ablation 75 
protocol respecting strict criteria for contiguity and quality lesion resulted in high rate of one-
year freedom from AF recurrence, both in patients with paroxysmal and persistent AF, 













































 This is the first multicenter study to demonstrate the high reproducibility of one-year 
outcome of AF radiofrequency catheter ablation using an ablation protocol respecting 
strict criteria for contiguity and quality lesion. 
 The high rate of one-year freedom from AF recurrence was observed both in patients 
with paroxysmal and persistent AF 125 
 The ablation catheters and the AI settings, chosen by the different operators, did not 



































Catheter ablation is a well-established treatment option for patients with symptomatic atrial 160 
fibrillation (AF) and is more successful at maintaining stable sinus rhythm than 
antiarrhythmic drugs. Pulmonary vein (PV) isolation is the cornerstone of catheter ablation in 
patients with both paroxysmal and persistent drug-refractory AF. The high rate of 
arrhythmias recurrence, mainly related to PV reconnection, and the wide outcome variability 
among several operators still remain the main limitations of AF catheter ablation (1-3). 165 
Recently, several technological improvements have been introduced to improve the 
efficiency of PV isolation. Among them, the Ablation Index (AI) (Biosense-Webster, 
Diamond Bar, California), a new marker of radiofrequency lesion quality, allowed a high rate 
of first pass pulmonary vein (PV) isolation (4-8) and a high single-procedure arrhythmia-free 
survival at 1 year (4-7). The aim of this prospective, multi-center study, is to evaluate the 170 
reproducibility and outcome of PV isolation guided by the AI. 
 
METHODS 
The Ablation Index Registry (AIR) (ClinicalTrials.gov Identifier: NCT03277976) is a 
prospective, multi-center, research study designed to evaluate the acute achievement of PV 175 
isolation with ThermoCool SmartTouch (ST) (Biosense-Webster, Diamond Bar, California) 
or ThermoCool SmartTouch surround flow SF (STSF) (Biosense-Webster, Diamond Bar, 
California) catheter using the AI Module. Enrollment started in November 2017 and ended in 
July 2018. The study was approved by local Ethics Committees and complied with the 
Declaration of Helsinki guidelines. Written informed consent was obtained from all patients. 180 
Study population and study protocol. Enrollment criteria and ablation protocol has been 
already described (8). Briefly, we enrolled patients with paroxysmal or persistent atrial 
fibrillation (AF) who underwent their first AF ablation. Each operator performed AF catheter 
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ablation using its own ablation technique as concerning the ablation catheter (ST or STSF) 
and the AI setting (380 posterior-500 anterior and 330 posterior-450 anterior). No 185 
randomization was required nor was there any deviation from the clinical practice of each 
center and operator. Therefore the enrolled population was divided in 4 groups: Group ST 
330-450, Group ST 380-500, Group STSF 330-450, and Group STSF 380-500.  
Ablation protocol. The ablation procedure has been already described (8). Briefly, the 
ablation was usually performed under effective oral anticoagulation, and antiarrhythmic 190 
drugs were usually withdrawn before scheduled procedure. Ablation was carried out under 
conscious sedation or general anesthesia according to operators’ preference. One or two 
transeptal accesses to the left atrium were achieved using a standard approach. Then, a 
duodecapolar circular mapping LASSO (Biosense-Webster, Diamond Bar, California) 
catheter and the ablation catheter (ST or STSF) were placed in the left atrium. Left atrium 195 
mapping was performed in sinus rhythm. Patients with AF at the beginning of the index 
procedure underwent electrical cardioversion. After left atrium reconstruction the effective 
PV-left atrium electrical connection was checked by LASSO catheter. Radiofrequency pulses 
were delivered using the 3.5-mm Thermocool ST or STSF Catheter in power control mode. 
Radiofrequency power was set between 20 and 35 W depending on different left atrial sites 200 
and the catheter tip was irrigated by saline at a flow rate of 2 mL/min during mapping and of 
8 mL/min (STSF) or 17 mL/min (ST) and 15 mL/min (STSF) or 30 mL/min (ST) for outputs 
of less than and greater than 30 W, respectively (9). Radiofrequency energy was delivered to 
produce a circumferential ablation around the proximal part of each PV’s ostium or around 
ipsilateral PVs according to the patient’s anatomy or operator’s preference. The lesion around 205 
the PV ostium was created by sequential point-by-point application of radiofrequency energy. 
Real-time automated display of RF applications (Carto VISITAGTM Module, Biosense 
Webster) was used with predefined settings of respiration adjustment, catheter stability (3 
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mm for 3 s), minimum contact force (3 g over minimum 25% of time), with the lesion tag 
display size of 3 mm, and AI thresholds: 450 for anterior wall and 330 for posterior wall, or 210 
500 for anterior wall and 380 for posterior wall. In case of dislocation, a new RF application 
reaching the AI target was applied. Maximal inter tag distance between 2 neighboring Visitag 
was ≤ 6 mm (4,10). Upon completion of circumferential ablation a circular mapping LASSO 
catheter was used to confirm PV isolation (first-pass isolation). In the absence of isolation 
after completing the circle, LASSO guided touch-up ablation was delivered until PV isolation 215 
was achieved. Resumption of left atrium to PV conduction  was evaluated at 30 minutes after 
ablation. In case of reconnection PVs were newly isolated targeting the points of electrical 
breakthrough.  
All patients underwent a post-procedural ECG. Post-procedure echocardiography or other 
imaging was at the operators’ discretion. 220 
Post-ablation management and follow-up.  Oral anticoagulation was continued the same 
day of the procedure for all patients and administered for at least 3 months or with no time 
limit in patients with a CHA2DS2-VASC score ≥ 2. Patients with paroxysmal AF were 
discharged without antiarrhythmic drugs. Patients with persistent AF were discharged with or 
without antiarrhythmic drugs according to clinician’s preference. Patients were scheduled for 225 
follow-up examinations 1,3,6, and 12 months after the initial treatment, and the clinical 
assessment of AF recurrence during the follow-up visits was performed by ECG and 24-hour 
Holter monitoring.    
Ablation was deemed successful in the absence of symptomatic or asymptomatic atrial 
tachyarrhythmias lasting more than 30 seconds identified on surface ECG or on 24-hour 230 
Holter monitoring, off antiarrhythmic drug therapy. In patients with persistent AF we 
considered the ablation successful in absence of symptomatic or asymptomatic atrial 
tachyarrhythmias regardless of antiarrhythmic drug therapy used. As early relapse of atrial 
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tachyarrhythmias within the first 3 months after RF ablation may be a transient phenomenon, 
this transition period was excluded from the final analysis (11). 235 
Statistical analysis. Continuous variables are expressed as mean ± standard deviation or 
median and interquartile range according to their distribution. Normality of data distribution 
was tested with Shapiro-Wilk test. Categorical variables are expressed as absolute number 
with percentage (%). Comparison among groups for continuous variables was performed by 
the unpaired Student T test or Mann-Whitney U test. Comparison of categorical variables 240 
among groups was performed by Chi square test. The rate of freedom from any atrial 
tachiarrhythmias was assessed by using the Kaplan-Meier curve. Statistical significance was 
set at a 2-tailed probability level of <0.05. All statistical analyses were performed using SPSS 
software (Version 24.0, IBM, Armonk, NY, US). 
 245 
RESULTS 
Study population. A total of 490 patients were enrolled: 96 patients in ST 330-450 Group, 
81 in ST 380-500 Group, 162 in STSF 330-450 Group, and 151 in STSF 380-500 Group. The 
clinical characteristics of the study population have been already reported (8). Briefly, the 
mean age was 59±11 years, 71% of patients were males, the mean body mass index was 250 
27.1±4.2, the mean left atrium volume was 104±49 ml, the mean left ventricle ejection 
fraction was 58±8, 394 (80.4%) patients had paroxysmal AF, 36.8% had hypertension, 6.3% 
had diabetes mellitus. The left atrium volume was significantly higher in Group ST 380-500, 
the left ventricle ejection fraction was significantly lower in Group ST 330-450. No other 
statistically significant difference was observed among the clinical characteristics of the four 255 
study groups.  
Procedural data. The mean procedural time was 127±64 min, with a mean fluoroscopy time 
of 400±404 s, and a mean radiofrequency time of 31.9±11.8 min. The rate of first-pass PV 
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isolation was 90±16%. Resumption of left atrium to PV conduction 30 minutes after ablation 
was observed in 5.6% of PVs. The rate of first-pass PV isolation was similar among the four 260 
study groups, whereas procedure (ST330 129±44 min, ST380 144±44 min, STSF330 120±72 
min, STSF380 125±73 min, p<0.001) and fluoroscopy time (ST330 542±285 s, ST380 
540±416 s, STSF330 257±356 s, STSF380 379±454 s, p<0.001) significantly differed (8). A 
complication (4 pericardial effusions, 2 transient phrenic nerve palsy, 1 cardiac tamponade, 1 
pneumonia) was observed in 8 (1,6%) patients without any difference among the four study 265 
groups (p=0.55). 
One year outcome. One year follow-up was available in 453/490 (92.5%) patients. At 12 
months follow-up a high rate of freedom from AF recurrences was observed in patients with 
both paroxysmal (91%) and persistent (83.3%, p=0.039) AF (Figure 1). There was no 
difference in the rate of atrial arrhythmias recurrence among the four study groups (4.5% in 270 
Group ST330-450, 12.2% in Group ST 380-500, 14.9% in Group STSF330-450, 9.4% in 
Group STSF380-500, p=0.083) (Figue 2). At 12 months follow-up the rate of atrial 
arrhythmias recurrence was also similar between patients treated with a ST (8%) and STSF 
catheter (12.1%, p=0.2) (Figue 3), between patients targeting an AI setting of 330-450 
(10.9%) or 380-500 (10.3%, p=0.64) (Figure 4), and among operators (p=0.84 and p=0.75, 275 
respectively, in patients with paroxysmal and persistent AF). 
 
DISCUSSION 
The present study demonstrates that an ablation protocol, respecting strict criteria for 
contiguity and quality lesion, resulted in high rate of one-year freedom from AF recurrence, 280 
both in patients with paroxysmal and persistent AF. The results were reproducible among 
different operators, and were not impacted by the ablation catheters and AI settings chosen. 
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PV isolation is considered the cornerstone of AF ablation in both paroxysmal and persistent 
AF. Despite the high acute success rate, achieving durable PV isolation has proven 
challenging. The high rate (up to 86%) of delayed recovery (12) in PV conduction has 285 
translated into disappointing single-procedure success rates (13). Recently a new 
radiofrequency lesion marker has demonstrated to improve the efficiency of PV isolation. De 
Pooter et al (14) studied 45 patients undergoing repeat ablation for AF recurrence after first 
AI guided PV isolation procedure. They found that the likelihood of finding 4 isolated PV at 
the time of repeat ablation for AF is 62%, higher than previously reported (15), concluding 290 
that  PV reconnection is no longer the rule in patients with AF recurrence. This finding might 
justify the favourable acute and 1-year outcome after a PV isolation strategy based on stable, 
contiguous, and optimized radiofrequency applications by means of AI (4-7). However all 
these studies were single center and, overall, enrolled 475 patients. In our multicentre study 
we confirm these findings observing about 90% rate of freedom from AF recurrence. 295 
Moreover we reported a high (> 80%) one year success rate also in patients with persistent 
AF. Our findings were not impacted by the catheter (ST or STSF) chosen nor above all by the 
AI setting.  
There is still a debate on the best AI values that allow effective, safe and durable PV 
isolation.  Das et al (16) studied the relationship between the AI and PV reconnection at 300 
repeat electrophysiology study. From receiver operating characteristic (ROC) curve analysis, 
optimal cutoff points (Youden Index) were calculated. For AI, the optimal cutoff for 
anterior/roof segments was 376 (sensitivity 63.6%, specificity 77.8%, and positive predictive 
value 97.2%) and for posterior/inferior segments was 340 (sensitivity 52.9%, specificity 
94.3%, and positive predictive value 98.2%). No late reconnection was seen in anterior/roof 305 
segments where the minimum AI value was ≥480 or in posterior/inferior segments where the 
minimum AI value was ≥370. El Haddad et al (17) studied acute and late PV reconnection. 
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By ROC curve analysis they found the highest (90%) specificity to predict durable PV 
isolation with an AI >550 on the anterior wall and >417 on the posterior wall. We have no 
data on late PV reconnection, however we did not observe any difference in one year 310 
outcome between an AI setting using higher (380-500) or lower (330-450) values. Our 
findings, might be justified by Ullah et al (15) series. They showed that ablation beyond 430 
AI provides minimal additional biophysical efficacy, suggesting an upper limit to use for 
clinical ablation.  
Reproducibility of AF catheter ablation still remains an unsolved issue (1). Radiofrequency 315 
ablation, the current most used energy source in most countries (3), of AF is a technically 
complex procedure, with a long-learning curve, and its results seem to largely depend on 
Centre’s experience. In recent years, cryoballoon ablation of AF has been introduced 
as an alternative ‘single-shot’ approach for PV isolation. Several multicenter studies (18,19) 
showed the higher reproducibility of cryoballoon ablation compared with standard 320 
radiofrequency ablation as regards mid-term outcomes of catheter ablation of AF, with lower 
inter-operator and inter-centre variability. We (8) have already demonstrated that AI guided 
PV isolation allows comparable rate of acute PV isolation among operator with different skill 
performing ablation with different catheters, AI settings, procedure and fluoroscopy times. 
The present study extends this finding on one-year outcome, confirming the high 325 
reproducibility of outcome when AF ablation is performed with a point-by-point approach, 
both in patients with paroxysmal and persistent AF. 
Limitations. Firstly, this is a non randomized study. No deviation from the clinical practice 
of each center and operator was required. Nevertheless, AF ablation registries offer a unique 
opportunity to collect data from large numbers of patients to examine outcomes. In particular, 330 
registries might help assess how ablation is being performed in the “real world” compared 
with controlled clinical trials that are often performed on a highly selected patient 
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population in very experienced centers. Secondly, a minority of patients (7.5%) were lost to 
follow-up. This can be explained by the fact that patients were frequently referred for 
ablation by their local cardiologists and were transferred to their care after discharge.  335 
Lastly, sinus rhythm maintenance was based mainly on patients’ symptoms, ECG and 
scheduled 24-hour Holter monitoring. Asymptomatic or short-lasting AF episodes may have 
occurred unnoticed, and our success rate may have been over-estimated.  
 
CONCLUSIONS 340 
In conclusion, an ablation protocol respecting strict criteria for contiguity and quality lesion 
resulted in high rate of one-year freedom from AF recurrence, irrespective of the ablation 
catheters, and AI settings. The result was reproducible among different operators, both in 
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FIGURE LEGENDS 430 
Figure 1. Kaplan–Meier estimation of the time to atrial arrhythmia recurrence after the 
blanking period in patients with paroxysmal and persistent patients. 
Figure 2. Kaplan–Meier estimation of the time to atrial arrhythmia recurrence after the 
blanking period in the four study groups. 
Figure 3. Kaplan–Meier estimation of the time to atrial arrhythmia recurrence after the 435 
blanking period in patients ablated with the ThermoCool SmartTouch (ST) or 
ThermoCool SmartTouch SF (STSF) catheter. 
Figure 4. Kaplan–Meier estimation of the time to atrial arrhythmia recurrence after the 
blanking period in patients ablated using the high (380-500) or low (330-450) AI setting. 
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